Related Experiment Video
Updated: Jun 19, 2026
10:49
Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds
Published on: August 21, 2021
Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate
E Jantratid1, S Strauch, C Becker
1Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany.
Journal of Pharmaceutical Sciences
|October 3, 2009
Summary
A biowaiver for in vivo bioequivalence testing is appropriate for immediate-release doxycycline hyclate oral forms. This is based on its Biopharmaceutics Classification System Class I status and low risk of bioinequivalence.
Area of Science:
- Pharmaceutical Sciences
- Drug Development
- Regulatory Science
Background:
- Doxycycline hyclate is an antibiotic commonly formulated as immediate-release (IR) solid oral dosage forms.
- Bioequivalence (BE) testing is crucial for drug product approval, but in vivo studies can be waived under certain conditions.
- The Biopharmaceutics Classification System (BCS) provides a framework for assessing drug product performance based on solubility and permeability.
Purpose of the Study:
- To review literature data supporting the waiver of in vivo bioequivalence testing for IR doxycycline hyclate oral dosage forms.
- To assess the suitability of doxycycline hyclate for BCS classification and its implications for biowaiver applications.
- To establish criteria for granting biowaivers for doxycycline hyclate IR formulations.
Main Methods:
- Literature review of existing data on doxycycline hyclate formulations, bioequivalence, and Biopharmaceutics Classification System (BCS) properties.
- Analysis of reported issues with bioequivalence of doxycycline hyclate IR products considering various excipients and manufacturing processes.
- Evaluation of BCS-based dissolution methods for their ability to predict therapeutic equivalence.
Main Results:
- Doxycycline hyclate can be classified under BCS Class I, indicating high solubility and high permeability.
- No significant issues with bioequivalence have been reported for IR doxycycline formulations with different excipients or manufacturing methods, suggesting a low risk.
- BCS-based dissolution testing is capable of identifying formulations that may not achieve therapeutic levels due to slow dissolution.
Conclusions:
- A biowaiver is deemed appropriate for IR solid oral dosage forms containing doxycycline hyclate as the sole Active Pharmaceutical Ingredient (API).
- Conditions for the biowaiver include the use of only approved excipients and compliance with BCS criteria for rapid or very rapid dissolution.
- The established criteria aim to ensure therapeutic equivalence without the need for in vivo bioequivalence studies, streamlining the drug approval process.
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:25Dosage Regimen: Multiple Oral Dosage
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...